PeproTech VEGF-165 Polyclonal Antibody, PeproTech®, Invitrogen™

Descripción

AA Sequence of recombinant protein: APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR. Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human VEGF 165. Anti-Human VEGF 165-specific antibody was purified by affinity chromatography employing an immobilized Human VEGF 165 matrix. Sandwich ELISA: To detect Human VEGF 165 by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.5-2.0 μg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human VEGF 165 (500-P10Bt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human VEGF 165. Western Blot: To detect Human VEGF 165 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human VEGF 165 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.

The vascular endothelial growth factor (VEGF) family currently includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and PIGF. VEGF and its receptor system have been shown to be the fundamental regulators in the cell signaling of angiogenesis. Most tumors have the absolute requirement of angiogenesis and VEGF has been described as the most potent angiogenic cytokine linked to this process. To date 5 different isoforms of VEGF have been described. These isoforms are generated as the result of alternative splicing from a single VEGF gene. These various isoforms have been shown to bind to two tyrosine-kinase receptors flt-1 (VEGFR-1) and flk-1/KDR (VEGFR-2), which have been found to be expressed almost exclusively on endothelial cells.